Clinical trials: Interstitial Fibrosis
Idiopathic Pulmonary Fibrosis
Exhaled Breath Condensate Biomarkers and Cough in IPF
Analysis of exhaled breath condensate biomarkers and cough severity in patients with idiopathic pulmonary fibrosis.
- Trial name
- NCT02630940
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- University of East Anglia
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF
Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b.
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
- Trial name
- NCT00076635
- Testing
- Interferon gamma-1b
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- InterMune
Pulmonary Fibrosis
Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies
The purpose of this study is to determine wether pirfenidone is safe and effective in the treatment of pulmonary fibrosis with anti-myeloperoxydase (MPO) antibodies or pulmonary fibrosis with anti-MPO associated vasculitis.
- Trial name
- PIRFENIVAS (NCT03385668)
- Testing
- Pirfenidone
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Pulmonary Fibrosis
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05537025
- Testing
- ARO-MMP7 Inhalation Solution
- Where
- 19 sites in Denmark, Italy and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Kidney Transplant, Kidney Transplantation
Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients
There is a need to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had kidney transplant.
- Trial name
- PROGENI-KI (NCT01289717)
- Where
- 5 sites in United States
- Volunteers
- 307 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Interstitial Lung Disease, Scleroderma
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
Interstitial lung disease (ILD) is characterised by inflammation and scarring of the lung and is the leading cause of death in patients with systemic sclerosis, and contributes significantly to morbidity and mortality in many…
- Conditions
- Interstitial Lung Disease, Scleroderma, Idiopathic Inflammatory Myositis, Mixed Connective Tissue Disease
- Trial name
- RECITAL (NCT01862926)
- Testing
- Rituximab, Cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Chronic Respiratory Diseases, Cystic Fibrosis
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
Assessment of cardiovascular disorders using echocardiography and arterial stiffness; comparative noninvasive assessment of volatile organic compound (eVOC) exhale breath patterns in patients with different chronic respiratory…
- Conditions
- Chronic Respiratory Diseases, Cystic Fibrosis, Lymphangioleiomyomatosis, Hypersensitivity Pneumonitis
- Trial name
- NCT05727852
- Testing
- Breath test using the Compact PTR-TOF-MS, Portable cardiac monitor "CardioQvark", Assessment of arterial stiffness using the VaSera VS-1500N
- Where
- Russia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Lung Fibrosis Interstitial, Post-COVID-19 Syndrome
Effect of Aerobic Exercises Versus Incentive Spirometer Device on Post-covid Pulmonary Fibrosis Patients
the aim of this study will be to investigate the effect of aerobic exercises vs incentive spirometer device on post-covid patients with residual lung diseases.
- Trial name
- NCT06191367
- Testing
- Aerobic Exercises, Incentive Spirometer Device, Traditional Chest Physiotherapy
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- McCarious Nahad Aziz Abdelshaheed Stephens
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
- Trial name
- NCT00625079
- Testing
- sildenafil
- Where
- United States
- Sponsor
- University of California, Los Angeles
Systemic Sclerosis Pulmonary, Pulmonary Hypertension
Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement
Progressive SSc is an entity with limited therapeutic alternatives and with asurvival rate of less than 45% in the first 3 to 5 years.
- Conditions
- Systemic Sclerosis Pulmonary, Pulmonary Hypertension, Pulmonary Fibrosis
- Trial name
- NCT04432545
- Testing
- Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly
- Where
- Colombia
- Sponsor
- Universidad de la Sabana
IPF, Pulmonary Fibrosis
The Effectiveness of Pulmonary Rehabilitation on Saturation in Patients With Idiopathic Pulmonary Fibrosis
The aim of this study is to evaluate the effects of a pulmonary rehabilitation (PR) program on health outcomes and the distance-saturation product in patients with IPF, by comparing two distinct groups: those who experience…
- Trial name
- NCT07031362
- Testing
- EXERCISE TRAINING WITH OR WITHOUT MEDICATION
- Volunteers
- 50 people
- Sponsor
- Izmir Katip Celebi University
Pulmonary Hypertension, Pulmonary Fibrosis
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
A phase 2b, open label study to assess the safety and efficacy of increasing doses of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis and sarcoidosis on long term oxygen therapy followed by a long term…
- Conditions
- Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
- Trial name
- NCT03727451
- Testing
- iNO
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bellerophon
Idiopathic Pulmonary Fibrosis
Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide
Octreotide is a somatostatin analog with a long half-life in vivo. Octreotide has interesting anti-inflammatory and anti-fibrotic properties in vitro and in vivo.
- Trial name
- FIBROSAND (NCT00463983)
- Testing
- octreotide
- Where
- 16 sites in France
- Volunteers
- 25 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Hiatal Hernia, Interstitial Lung Disease
Hiatal Hernia and Pulmonary Involvement
Patients often present with a significant burden of fibrosis upon diagnosis as there is interest in identifying these individuals earlier in their disease course (i.e., "subclinical disease") where targeted treatments and…
- Trial name
- NCT05716022
- Testing
- Blood Collection, Bronchoscopy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Virginia
Pulmonary Fibrosis, COVID-19 Respiratory Infection
Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19
The COVID-induced fibrotic lung damage continues long after viral infection has subsided and is exhibited by severe respiratory pathology and concomitant symptoms.
- Trial name
- NCT05387239
- Testing
- VL-PX10 and VL-P22 plus standard care
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vitti Labs, LLC
Idiopathic Pulmonary Fibrosis
Phase ll Study of HEC585 in Patients With IPF
A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with idiopathic pulmonary fibrosis
- Trial name
- NCT05060822
- Testing
- HEC585, Pirfenidone
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Idiopathic Pulmonary Fibrosis (IPF)
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
A multicenter, parallel, randomized, placebo (double-blind) and pirfenidone (open-label) controlled Phase III clinical trial to evaluate the efficacy and safety of HEC585 in patients with idiopathic pulmonary fibrosis (IPF)
- Trial name
- NCT07082842
- Testing
- HEC585, Pirfenidone
- Where
- China
- Volunteers
- 472 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Idiopathic Pulmonary Fibrosis (IPF)
To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers
This is a Phase I stage to investigate the safety and tolerability of MG-S-2525 in healthy volunteers. The proposed trial consists of 3 study parts to be conducted at Tri-Service General Hospital and includes Single Ascending…
- Trial name
- NCT03650075
- Testing
- MG-S-2525
- Where
- Taiwan
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Metagone Biotech Inc.
Chronic Obstructive Pulmonary Disease, Asthma
Controls for Respiratory Diseases
This is the registry of control participants for patients with various respiratory diseases. We screened healthy volunteers who visited Seoul National Hospital Healthcare System Gangnam Center for routine health check-up, and…
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Idiopathic Pulmonary Fibrosis, Nontuberculous Mycobacterium Infection
- Trial name
- NCT03120481
- Testing
- no intervation
- Where
- South Korea
- Volunteers
- 1,572 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Toward Self-management in ILD
Treating and caring for people with long term conditions accounts for a substantial proportion of health care resources. Self-management is advocated as a mechanism that can empower service users with long term conditions to…
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Connective Tissue Related ILD, Chronic Hypersensitivity Pneumonitis
- Trial name
- NCT03300583
- Testing
- Focus groups, Semi-structured interviews
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Kingston University